Dr. Farraye is a Senior Associate Consultant in the Section of Gastroenterology and Hepatology at the Mayo Clinic in Jacksonville Florida where he co-directs the Inflammatory Bowel Disease Center. Prior to relocating in 2019, he was Clinical Director in the Section of Gastroenterology and the Inflammatory Bowel Disease Center at Boston Medical Center. At Chobanian and Avedisian School of Medicine, he was Professor of Medicine. Dr. Farraye earned his medical doctorate from the Albert Einstein College of Medicine in New York and his master’s degree in Epidemiology from the Harvard School of Public Health.
Dr. Farraye’s clinical interests are in the care of patients with inflammatory bowel disease. He is currently investigating C. difficile infection in IBD patients, the management and diagnosis of dysplasia and cancer in patients with IBD; social media use and health literacy in IBD patients; hepatitis B vaccination efficacy in patients with IBD; and subclinical hepatic fibrosis in patients with IBD.
A frequent speaker and invited lecturer on topics on the diagnosis and management of inflammatory bowel disease, Dr. Farraye has authored or co-authored over 450 original scientific manuscripts, book chapters, reviews, and abstracts. He is the series editor for the text Curbside Consultations in Gastroenterology and co-edited the text, Curbside Consultation in Inflammatory Bowel Disease and Gastrointestinal Emergencies. His books for patients include Questions and Answers about Ulcerative Colitis, Questions and Answers about Crohn’s Disease and Ulcerative Colitis for Dummies.
Dr. Farraye is a Fellow of the American Society of Gastrointestinal Endoscopy, American Gastroenterological Association and the American College of Gastroenterology. He has served on numerous national and international committees including as a member of the ACG Board of Trustees. He is co-chair of the Crohn’s and Colitis Foundation Membership Committee and a member of the Chapter Medical Advisory Committee for the New England Crohn’s and Colitis Foundation and a past chairman. The New England Crohn’s and Colitis Foundation named Dr. Farraye Humanitarian of the Year in 2003. In 2009, the ACG awarded Dr. Farraye the William Carey Award for service to the college. Dr. Farraye has been recognized as “Top Doctor” in Gastroenterology by Boston Magazine and U.S. News and World Report since 2010.
- Member, Center for Regenerative Medicine, Boston University
- Member, Evans Center for Interdisciplinary Biomedical Research, Boston University
- Albert Einstein College of Medicine, MD
- Harvard School of Public Health, MSc
- Stony Brook University, BS
- Published on 10/9/2023
Santiago P, Coelho-Prabhu N, Lennon R, Rui S, Rajauria P, Friton J, Raffals LE, Deepali F, Daoud N, Farraye FA, Tuck J, Malik T, Leleiko NS, Shapiro J, Shah SA, Sands BE, Ungaro RC. Baseline Clinical Factors Are Associated With Risk of Complications in Crohn's Disease: Appraisal of the American Gastroenterological Association Clinical Care Pathway. Am J Gastroenterol. 2023 Oct 09. PMID: 37713528.
- Published on 10/3/2023
Caldera F, Richard L, Almasry M, Phan H, Chun K, Farraye FA, Hayney MS. Persistence of Antibodies Six Months after Three COVID-19 mRNA Vaccine Doses in Patients with Inflammatory Bowel Disease. Inflamm Bowel Dis. 2023 Oct 03; 29(10):1662-1666. PMID: 36788133.
- Published on 10/3/2023
Schell TL, Ramirez O, Almasry M, Farraye FA, Hayney MS, Caldera F. Additional COVID-19 Booster Doses Increase Anti-spike Serum Antibody Concentrations Among Patients With Inflammatory Bowel Disease. Inflamm Bowel Dis. 2023 Oct 03; 29(10):e38-e39. PMID: 37071782.
- Published on 10/3/2023
Desai A, Deepak P, Cross RK, Murone J, Farraye FA, Ungaro RC, Kochhar GS. Effect of 2 vs 3 Doses of COVID-19 Vaccine in Patients With Inflammatory Bowel Disease: A Population-based Propensity Matched Analysis. Inflamm Bowel Dis. 2023 Oct 03; 29(10):1563-1571. PMID: 36576102.
- Published on 9/27/2023
Yang MM, Usiskin K, Ahmad HA, Ather S, Sreih A, Canavan JB, Farraye FA, Ma C. Considerations for Colorectal Neoplasia Detection in Inflammatory Bowel Disease Clinical Trials. Dig Dis. 2023 Sep 27. PMID: 37757769.
- Published on 9/6/2023
Desai A, Hashash JG, Kochhar GS, Farraye FA. Tixagevimab and Cilgavimab (Evusheld) as Pre-exposure Prophylaxis for COVID-19 in Patients With Inflammatory Bowel Disease: A Propensity Matched Cohort Study. Crohns Colitis 360. 2023 Jul; 5(3):otad047. PMID: 37680248.
- Published on 9/4/2023
El Hage Chehade N, Ghoneim S, Shah S, Pardi DS, Farraye FA, Francis FF, Hashash JG. Efficacy and Safety of Vedolizumab and Tumor Necrosis Factor Inhibitors in the Treatment of Steroid-refractory Microscopic Colitis: A Systematic Review and Meta-analysis. J Clin Gastroenterol. 2023 Sep 04. PMID: 37668427.
- Published on 9/1/2023
Loeb L, Nasir A, Picco MF, Hashash JG, Kinnucan JA, Farraye FA. Prior Authorization of Biologics in the Management of Inflammatory Bowel Disease. Inflamm Bowel Dis. 2023 Sep 01; 29(9):e37. PMID: 37196096.
- Published on 8/4/2023
Desai A, Soni A, Hayney MS, Hashash JG, Kochhar GS, Farraye FA, Caldera F. Increased Risk of Herpes Zoster in Adult Patients with Inflammatory Bowel Disease After SARS-CoV2 Infection: A Propensity-Matched Cohort Study. Inflamm Bowel Dis. 2023 Aug 04. PMID: 37540900.
- Published on 8/1/2023
Caldera F, Farraye FA, Necela BM, Cogen D, Saha S, Wald A, Daoud ND, Chun K, Grimes I, Lutz M, Van Helden SR, Swift MD, Virk A, Bharucha AE, Patel TC, Gores GJ, Chumsri S, Hayney MS, Knutson KL. Higher Cell-Mediated Immune Responses in Patients With Inflammatory Bowel Disease on Anti-TNF Therapy After COVID-19 Vaccination. Inflamm Bowel Dis. 2023 Aug 01; 29(8):1202-1209. PMID: 36103273.
View 448 more publications: View full profile at BUMC